The out-of-the-match and in-form players after the "big change of blood" in the health insurance catalogue.

Pharmaceutical Network August 3rd, health insurance policy adjustment curtain to open, drugs who go who stay, the rules finally finalized. On the evening of July 31,
, the State Administration of Medical Insurance officially announced the Interim Measures for the Administration of Drug Use in Basic Medical Insurance (hereinafter referred to as the Measures), the full text is attached to the end of the text.
although the high-profile Class B OTC drugs have remained in this round, but the Measures provide that no new Class B OTC drugs.
at the same time, eight categories of "god medicine" to set aside a place for more high-priced, high-demand good drugs.
who to retain: Class B OTC for the adjustment of the health insurance catalog, the industry is most concerned about the Category B OTC to stay, that is, can be bought in convenience stores, supermarkets over-the-counter drugs, such as co-pak, plate blue root, aspirin and so on.
the Interim Measures for the Administration of Drug Use in Basic Medical Insurance (Draft for Comments) published in April this year, had planned to exclude Class B OTC from the health insurance catalogue.
just 3 months, why has the health insurance catalog changed its attitude towards Class B OTC drugs? "The design of Class B OTC was designed to facilitate patients' self-care, while also reducing the workload of medical staff, but this has also led to drug abuse.
" medical expert Zhao Heng told reporters that the adjustment of health insurance policy is the general trend, the current adjustment can be called "go fast", but at the same time, the adjustment of health insurance should also "go steady". Zhao Heng,
, said that if the Class B OTC withdraws from the health insurance catalog, it will have a huge impact on the pharmaceutical retail industry.
"If Class B OTC drugs cannot be reimbursed and patients will be more likely to go to community hospitals, retail pharmacies will lose stable traffic and break the existing marketing system."
," Zhao said.
and the 2019 edition of the Health Insurance Catalog contains 2,709 drugs, of which 617 are OTC drugs and 121 are Class B OTC drugs, meaning that Class B OTC drugs account for only 4% of the total health insurance catalog.
and this 4% for pharmaceutical companies, for the market, but it is a hair-pulling whole body. according to public data
, in the latest version of the National Health Insurance Directory, the sales revenue of Class B OTC drugs in 2019 reached 15.728 billion yuan, involving 85 pharmaceutical listed companies.
Class B OTC drug hospital revenue accounted for more than 10% of the company's total operating income of 8 companies, accounting for the highest share of Newstone even reached 67.75 percent.
during this year's "two sessions" of the National People's Congress, deputies to the National People's Congress also proposed to retain The Health Insurance Catalog of Class B OTC drugs.
, the National People's Congress representative, Treasure Island Pharmaceuticals Chairman Fang Tonghua said: "Class B OTC drugs have long been in the medical insurance catalog, base drug catalog occupies a certain proportion, patients of Class B OTC drugs awareness, high acceptance."
in addition, Class B OTC drugs are safe, clear efficacy, low price, medical insurance into a certain Class B OTC drugs can meet the clinical needs of China's medical treatment, reduce the pressure of patients' health insurance.
", however, whether class B OTC remains in the health care catalog, the core is in the health care policy reform and combing.
China Over-the-Counter Drug Association pointed out that OTC health insurance policy reform should be improved from payment channels and payment methods, medical insurance catalog should be included in the clinical lysa, safe and effective, reasonable price basic conditions, it is not appropriate to "otC" as the determinant of health insurance catalog.
however, the Measures also make it clear in Article 36 that, in principle, the Drug Catalog will no longer add OTC drugs.
this also means that in the future Class B OTC drugs also have no chance to enter the health insurance catalog.
who was kicked out: "God drug" failed Class B OTC to retain health insurance eligibility, but preventive vaccines, health care products, treatment of hair loss, weight loss of beauty drugs and other eight categories were kicked out of the health insurance catalog.
in fact, these eight types of drugs are mostly "improved" drugs, that is, the effect is not obvious, the composition is similar, gold oil-like "god medicine." more
more importantly, the Measures will come into force on 1 September 2020.
this means that the time left for the relevant drug companies to adjust is running out, especially the clinical value of inaccurate and can be better replaced drugs, will be limited clinical use and health insurance does not pay the double blow, after being transferred out of the health insurance catalog is bound to be the original market will shrink significantly.
seems sudden, and the actual "clean-up" has already begun.
last August, the Guizhou Provincial Medical Security Bureau issued a notice requesting that health care products be transferred out of the scope of payment of the employee's basic medical insurance personal account, and late last year, Beijing issued the Notice on Adjusting the scope of reimbursement of basic medical insurance, industrial injury insurance and maternity insurance drugs in the city, which removed 352 drugs.
entered this year, the State Health Insurance Bureau Director Hu Jinglin has repeatedly written, speech, the health insurance directory of the "god medicine" devouring the health insurance fund, in particular, in particular, these safety and ineffective "god medicine" for a long time, "only into", affecting the masses to access high-quality drug services.
recently In-11 provinces of Zhejiang, Yunnan and other health insurance bureaus in June, clear a number of transfer out of the local medical insurance supplementary varieties.
According to incomplete statistics, there are more than 1500 drugs from July 1 out of the local health insurance directory, no longer enjoy medical insurance reimbursement. Zhu Minglai, director of the Center for Health Economy and Medical Security Research at Nankai University in
, told reporters that the biggest bright spot of the adjustment of the health insurance policy is that it can be moved in and out, and the market is advanced, in-demand drugs transferred into the catalog, "God medicine" culled, which will improve the structure of China's drug market, further improve the efficacy and quality of drugs, as well as the future pharmaceutical market is good.
the industry generally believes that these so-called "god drugs" accounted for a significant proportion of the serious waste of health-care funds.
and this time the medical insurance catalog drug regulations, there will undoubtedly be a large number of "god medicine" forced out, to achieve the reform of cage-for-bird.
with the third batch of collection is imminent, more high-priced rare disease drugs, anti-cancer drugs, chronic drugs will enter the health insurance catalog, at this time "kicking out" a large number of drugs, is undoubtedly in the above-mentioned drugs to make the ground.
new entrants: the third batch of collection to open a large number of drugs out, health insurance catalog is vacant, who is waiting for? On July 29, Shanghai Sunshine Pharmaceutical Procurement Network announced the official documents of the national centralized procurement of drugs, which means that the third batch of national collection officially began.
and the first two batches of focus on anti-cancer drugs, this collection is more in favor of the time span, high cost of chronic disease drugs, such as antihypertensive drug procesatan, diabetes treatment drug metformin and so on. according to the
public information, the total sales of 56 generic drugs in 2019 in China's public medical institutions exceeded 56 billion yuan, of which 23 drug sales exceeded 1 billion yuan, and 14 generic drugs can compete with 5 or more enterprises.
means that the collection is far more competitive than it used to be.
in the second set of metformin in the current round smoothly entered the collection list, but its "killing" is also divided into several categories.
as China's oral blood glucose regulating drug market share of the second-largest drug, metformin market share of about 19%, 2018 in China's public medical institutions, physical pharmacies and other sales terminals, the total market size of more than 6 billion yuan.
public information shows that the original pharmaceutical company of metformin is the Swiss pharmaceutical giant Merck, according to incomplete statistics, its domestic potential rivals about 16, including Huaxin Pharmaceuticals, Stone Pharmaceutical Group, Zhengda Tianqing and other domestic head pharmaceutical companies.
health insurance catalog has been left early, and this position is only for "cheap" drugs.
Although it is not possible to predict the pricing of metformin, at the end of last year, Hebei Province collected 500 million tablets of metformin oral frequently released agent form, the final winning stone drug europahydrochloride tablets (0.5g) per tablet only 0.043 yuan / tablet.
the price is 57.9% lower than its maximum price of 0.102 yuan per chip.
and stone drugs can be so price-to-price because its hydrochloric acid metformin raw materials for the group's own production.
contacted Stone Pharmaceutical Group for an interview, as of the writing, did not receive a reply.
in addition to metformin, omeprazole is also nicknamed "the murder" of the group.
omeprazole is a super-large variety of digestive tract medications, clinically used in the stomach, duodenal ulcers, reflux esophagitis, etc., its world-highest sales once exceeded 6 billion U.S. dollars.
data show that omeprazole intestinal capsule 20mg this product size of about 1.5 billion yuan, 10mg also has 300 million yuan.
and metformin has a number of competitors of the pattern is different, omeprazole "big plate, less enterprise", the current competitive landscape of 5 to 4.
according to statistics, Changzhou four-drug pharmaceutical omeprazole intestinal capsules in China has nearly 65% of the market share.
in this collection, with Changzhou four pharmaceutical pharmaceutical direct competition will be Shandong Luoxin, Hainan Hailing, Yangzijiang and the original research AstraZeneca.
.